The estimated Net Worth of Scott W Morrison is at least $1.07 Million dollars as of 24 June 2024. Mr. Morrison owns over 3,350 units of Global Blood Therapeutics stock worth over $320,739 and over the last 9 years he sold GBT stock worth over $145,008. In addition, he makes $599,495 as Independent Director at Global Blood Therapeutics.
Scott has made over 6 trades of the Global Blood Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,350 units of GBT stock worth $229,442 on 24 June 2024.
The largest trade he's ever made was selling 4,800 units of Global Blood Therapeutics stock on 9 September 2021 worth over $145,008. On average, Scott trades about 498 units every 35 days since 2016. As of 24 June 2024 he still owns at least 4,683 units of Global Blood Therapeutics stock.
You can see the complete history of Mr. Morrison stock trades at the bottom of the page.
Scott W. Morrison CPA serves as Independent Director of the Company. From 1996 to December 2015, Mr. Morrison was a partner at Ernst & Young LLP, a public accounting firm, and served as its U.S. Life Sciences Leader since 2002. He currently serves on the board of directors of Corvus Pharmaceuticals, Inc., a biopharmaceutical company and Ideaya Biosciences, Inc., a biotechnology company. Mr. Morrison served on the board and chaired the audit committee of Audentes, Inc. from December 2015 through its sale to Astellas Pharma Inc. in January 2020. Mr. Morrison has served on numerous life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Bioscience Center Board (now California Life Sciences Association), the California Life Sciences Foundation and the Biotechnology Institute. Mr. Morrison holds a B.S. in Accounting and Finance from the University of California, Berkeley and is a Certified Public Accountant (inactive). Mr. Morrison’s qualifications to serve on our Board of Directors include significant accounting expertise and knowledge of the life sciences industry through his 35-year career in public accounting serving public and private companies in the life sciences sector, as well as his experience serving on the board of directors (and certain key standing committees) of other biotechnology companies since 2015.
As the Independent Director of Global Blood Therapeutics, the total compensation of Scott Morrison at Global Blood Therapeutics is $599,495. There are 14 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
Scott Morrison is 62, he's been the Independent Director of Global Blood Therapeutics since 2016. There are 5 older and 13 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
Scott's mailing address filed with the SEC is 15440 LAGUNA CANYON ROAD, SUITE 160, , IRVINE, CA, 92673.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third..., and Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: